Brief: Inventiva And Hepalys Pharma, Inc. Announce Exclusive Licensing Agreement To Develop And Commercialize Lanifibranor In Japan And South Korea
20/09/2023 22:16
Inventiva SA IVAA.PA :
* INVENTIVA AND HEPALYS PHARMA, INC. ANNOUNCE EXCLUSIVE
LICENSING
AGREEMENT TO DEVELOP AND COMMERCIALIZE LANIFIBRANOR IN JAPAN AND
SOUTH KOREA
* INVENTIVA SA - UNDER EXCLUSIVE LICENSING AGREEMENT,
INVENTIVA
WILL RECEIVE A $10 MILLION UPFRONT PAYMENT
* INVENTIVA SA - UNDER EXCLUSIVE LICENSING AGREEMENT,
INVENTIVA IS
ELIGIBLE TO GET UP TO $ 231 MILLION IN CLINICAL, REGULATORY &
COMMERCIAL MILESTONE PAYMENTS
Source text for Eikon: ID:nGNX6wRyBN
Further company coverage: IVAA.PA
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030